Condition

Postmenopause

ClinicalTrials.gov condition label

Clinical trials16

Recruiting2

Common interventions25

Lead sponsors shown12

Clinical trials

16 shown

Effects of a Dietary Intervention Based on the Dietary Guidelines for the Brazilian Population on the Reduction of Menopausal Symptoms in Overweight and Obese WomenNCT07822230 · 2026-05-06

Prehabilitation With Resistance-exercise Training for Breast Cancer Neoadjuvant TherapyNCT06309290 · 2025-01-01

Resistance-type Exercise Training in Postmenopausal Women Survivors of Breast CancerNCT05690295 · 2023-03-22

Diet for the Maintenance of Weight Loss and Metabolic Health in Obese Postmenopausal WomenNCT04136093 · 2020-02-29

Beetroot Supplementation in Women Enjoying Exercise TogetherNCT04370756 · 2020-01-30

Effect of Resistance Training Variable Manipulation in Postmenopausal Breast Cancer Survivors.NCT03644329 · 2018-05-13

A Treatment With Fulvestrant and Exemestane in Postmenopausal Patients With Advanced Hormone Receptor-Positive (HR) + Breast CancerNCT01171417 · 2010-08-01

Treatment of Hot Flushes in Breast Cancer Patients With AcupunctureNCT00425776 · 2007-02-01

Effects of Angeliq and Prempro on Blood Pressure and Sodium Sensitivity in Postmenopausal Women With PrehypertensionNCT00420342 · 2007-01-01

Effect of Angeliq on Blood Pressure (BP) in Postmenopausal Hypertensive WomenNCT00102141 · 2004-04-01

AFTER: Altering Fat Through Estrogen and RaloxifeneNCT00149604 · 2000-03-01

Lifestyle Management for Women With CHD and NIDDMNCT00005441 · 1993-04-01

Women's Healthy Lifestyle Project: Cardiovascular Risk Factors and MenopauseNCT00000532 · 1992-02-01

Postmenopausal Estrogen/Progestin Interventions (PEPI)NCT00000466 · 1987-09-01

Nurses' Health Study (Cardiovascular Component)NCT00005152 · 1980-08-01

ACTIVE_NOT_RECRUITING

Women's Health Initiative (WHI)NCT00000611

Common interventions

diet, fat-restrictedBEHAVIORAL2 estrogen replacement therapyDRUG2 acupunctureDEVICE1 Angeliq (Drospirenone/17ß-estradiol, BAY86-4891)DRUG1 Beetroot JuiceDIETARY_SUPPLEMENT1 calciumDRUG1 conjugated estrogensDRUG1 Control dietOTHER1 Control groupOTHER1 dietary supplementsBEHAVIORAL1 Drospirenone/17ß-estradiol (Angeliq, BAY86-4891)DRUG1 estrogensDRUG1 estrogens, conjugatedDRUG1 exercise plus mild caloric restriction for weight lossBEHAVIORAL1 Exercise TrainingOTHER1 Higher-load resistance training (HL)OTHER1 Higher-volume resistance training (HV)OTHER1 hormone replacement therapyDRUG1 Lower-load resistance training (LL)OTHER1 medroxyprogesteroneDRUG1 Nutritional guidelines on healthy eating based on the Dietary Guidelines for the Brazilian Population in printed material and 5 in-person and virtual meetingsOTHER1 Nutritional guidelines on healthy eating based on the Dietary Guidelines for the Brazilian Population only in printed materialOTHER1 PlaceboDRUG1 Prehabilitation with resistance-exercise trainingOTHER1 progesteroneDRUG1

Leading sponsors

National Heart, Lung, and Blood Institute (NHLBI)3 Bayer2 Universidad de La Frontera2 AstraZeneca1 Brigham and Women's Hospital1 Federal University of Health Science of Porto Alegre1 Indiana University1 National Institute on Aging (NIA)1 Oregon Research Institute1 Poznan University of Life Sciences1 Universidade Federal do Triangulo Mineiro1 Vejle Hospital1

Trial status mix

COMPLETED11

RECRUITING2

UNKNOWN2

ACTIVE_NOT_RECRUITING1

Phase mix

NA6

PHASE34

PHASE22

PHASE11

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.